Aurobindo Pharma has received a Form 483 with one observation from the US FDA after an inspection of its formulation production facility in Andhra Pradesh. The observation is procedural in nature and the company intends to respond to the FDA and work to resolve the issue promptly. A Form 483 is issued when violations of relevant acts are observed during an inspection.